Lung Cancer
Conditions
Keywords
Lung Cancer, HepaSphere
Brief summary
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA）for lung cancer.
Detailed description
By enrolling patients with lung cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA）for lung cancer.
Interventions
PROCEDUREinterventional therapy
lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Sponsors
Fuda Cancer Hospital, Guangzhou
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age:18-80 2. Karnofsky performance status \>60 3. Diagnosis of lung cancer based on histology or the current accepted radiological measures. 4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ 5. Will receive interventional therapy 6. Life expectancy: Greater than 3 months 7. Patients' routine blood test, liver function and kidney function have no obvious abnormalities 8. Ability to understand the study protocol and a willingness to sign a written informed consent document
Exclusion criteria
1. Patients with other primary tumor except lung cancer 2. History of coagulation disorders or anemia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with Adverse events | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of lesions interventional therapy that show no sign of recurrence 12 months after | 1 year |
| Progress free disease (PFS) | 1 year |
| Overall survival (OS) | 3 year |
Countries
China
Outcome results
None listed